Blog

The Biopsychosociotechnical (BPST) model is a systems-based framework for health improvement that extends the traditional Biopsychosocial (BPS) model by incorporating the role of technology. In HealthTech, this model is a key framework to watch in 2026 as it advocates for a more holistic, human centered and practical approach to designing and implementing healthcare technologies.The BPST model views health and its determinants as a complex adaptive system of systems involving the interaction of four major domains:Biological (bio−): Genetics, physical health, disease pathology, physiological function. Psychological (psycho−): Thoughts, emotions, behaviors, coping mechanisms, mental health. Social (social−): Socioeconomic factors, culture, support networks, community and social determinants of health. Technical (techno−): The tools, technology, tasks, environments and organisational processes (eg. Electronic Health Records (EHRs), mobile health apps, AI, remote monitoring devices). &nbsp; Relevance in Healthtech for 2026 The BPST model provides a "practical theory" for health improvement, making it highly relevant as digital health technologies become more integrated and complex.1. Human-Centered Design and Implementation The model calls for a participatory design process that ensures technology is not just medically sound, but also psychologically and socially supportive.Focus: Designing health technologies that seamlessly integrate into the patient's real-world social context and address potential psychological barriers (eg. anxiety, stigma, digital literacy). 2026 Trend: A push toward personalised digital health products and platforms where the technical solution is tailored to the individual's specific biological, psychological and social circumstances. 2. Addressing Health Disparities By explicitly including the social and techno components, the BPST model forces a consideration of how technology can reduce or inadvertently worsen health inequalities.Focus: Designing and implementing technology to be accessible and effective across diverse populations, acknowledging differences in digital access, cultural beliefs and socioeconomic status. 2026 Trend: The use of technology to support inclusion health groups and address social determinants of health, ensuring that AI-driven diagnostics and remote care are equitable. 3. Systemic Intervention Management The model moves beyond simple "treatments" to focus on systems-focused interventions that modify the entire BPST context.Focus: Utilising technology to create holistic, continuous-care systems rather than isolated solutions. For example, remote patient monitoring (techno−) needs to be integrated with care coordination (social−) and psychological support (psycho−) to manage a chronic biological condition (bio−). 2026 Trend: Growing focus on Intervention Management to support the full lifecycle of health improvement, including continuous monitoring, feedback loops, and dynamic adjustments based on real-world system data. In short, the BPST model serves as the theoretical underpinning for the next generation of health technologies that must function as interconnected components within a patient's entire life and healthcare ecosystem, not just as isolated medical tools.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Biopsychosociotechnical (BPST) Models: One to Watch in HealthTech 2026

The National Health Service (NHS) is currently undergoing a fundamental transformation, mandated by the government’s 10 Year Health Plan, which prioritises the shift from analogue to digital operations. This strategic commitment frames AI adoption not merely as an efficiency measure, but as a critical requirement for securing the NHS’s future financial sustainability. Key objectives of this ambitious plan include moving "from bricks to clicks" and granting patients control over a single, secure and authoritative account of their health data, a unified patient record, which facilitates more coordinated, personalised, and predictive care models. &nbsp;&nbsp; Crucially, the government has established a mechanism to enforce continuous digital investment, requiring all NHS organisations, for the first time, to reserve a minimum of 3% of their annual expenditure specifically for one-time investments in service transformation. This policy is designed to overcome historical underinvestment in technology and accelerate the translation of proven innovations, such as the AI trial results, into national practice. This mandated capital expenditure mechanism ensures that the necessary financial foundation exists to integrate large-scale digital tools like Microsoft 365 Copilot, providing a sustained route away from dependence on archaic or legacy IT systems. The modernisation effort is thus inextricably linked to structural fiscal sustainability.The adoption of AI productivity tools is directly motivated by the significant administrative burden placed upon NHS staff. Health innovation leadership, including clinicians, recognises the deep frustration caused by "archaic technology that makes day-to-day tasks painstakingly long". The core mandate of the Microsoft 365 Copilot trial was explicitly to target this administrative friction, thereby freeing up staff "to focus on what they want to be doing - treating patients". &nbsp;&nbsp; The highly successful initial adoption of M365 Copilot is predominantly anchored in its application to generic "knowledge-worker tasks" across the organisation. These tasks include high-volume, non-clinical documentation such as handling Freedom of Information requests, documenting critical incidents, and automating Human Resources inquiries. This strategic focus on reducing friction in non-clinical documentation minimises exposure to immediate clinical risk, establishing M365 Copilot as an optimal, low-risk, first-wave model for large-scale generative AI deployment within the NHS.Source: <a data-mce-href="https://www.healthcare.digital/single-post/the-nhs-productivity-imperative-strategic-analysis-of-the-microsoft-365-copilot-trial-and-the-path" href="https://www.healthcare.digital/single-post/the-nhs-productivity-imperative-strategic-analysis-of-the-microsoft-365-copilot-trial-and-the-path" title="https://www.healthcare.digital/single-post/the-nhs-productivity-imperative-strategic-analysis-of-the-microsoft-365-copilot-trial-and-the-path" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/the-nhs-productivity-imperative-strategic-analysis-of-the-microsoft-365-copilot-trial-and-the-path</a>

Strategic Analysis of the NHS and Microsoft 365 Copilot Trial

The Regulatory Vanguard: Assessing the MHRA AI Airlock and the UK’s Potential for Leadership in Ambient Voice Technology Governance &nbsp;&nbsp; Strategic Context: The UK’s Principles-Based Approach to AIaMD Regulation &nbsp;&nbsp; The governance of Artificial Intelligence as a Medical Device (AIaMD) presents unique challenges related to algorithmic adaptivity, transparency, and assurance of continuous safety. The UK’s regulatory approach to this domain is strategically defined by a commitment to agility and innovation, leveraging existing sectoral regulators rather than relying on monolithic, preemptive legislation. &nbsp;&nbsp; The Policy Divergence: Agility vs. Prescription in Global AI Governance &nbsp;&nbsp; The foundation of the UK’s ambition is laid out in its National AI Strategy, which aims to establish the country as a "global AI superpower" by fostering "the most trusted and pro-innovation governance framework". This philosophical stance emphasises a context-sensitive, iterative approach that allows for adaptation by specialised regulators, such as the Medicines and Healthcare products Regulatory Agency (MHRA). This model deliberately contrasts with the comprehensive and prescriptive legislative approaches adopted in other major jurisdictions, notably the European Union’s AI Act. The strategic decision is driven by a mandate to avoid introducing "new rigid and onerous legislative requirements" that could potentially impede the rapid advancement of AI innovation. &nbsp;&nbsp; The UK framework rests on five cross-sectoral principles, intended to guide the development and deployment of AI systems across all regulated industries: safety, security and robustness; appropriate transparency and explainability; fairness; accountability and governance; and contestability and redress. By delegating the interpretation and operationalisation of these high-level principles to expert sectoral bodies, the UK hopes to maintain greater flexibility in managing sector-specific risks. &nbsp;&nbsp; This decentralised, principles-based model, however, carries an inherent structural tension. While it grants high operational flexibility, it simultaneously shifts the burden of interpreting these broad principles into concrete, technical compliance requirements onto the regulated manufacturers. This regulatory uncertainty can, in the initial stages, introduce friction for developers seeking market authorization. The central mechanism designed to mitigate this risk, translating conceptual principles (like Fairness and Accountability) into empirical, sector-specific technical requirements (such as validation protocols for specific datasets or robust post-market surveillance methods) is the MHRA’s AI Airlock. The Airlock thus functions as the essential, agile bridge between high-level policy ambition and pragmatic regulatory implementation.Source: <a data-mce-href="https://www.healthcare.digital/single-post/the-regulatory-vanguard-assessing-the-mhra-ai-airlock-and-the-uk-s-potential-for-leadership-in-ambi" href="https://www.healthcare.digital/single-post/the-regulatory-vanguard-assessing-the-mhra-ai-airlock-and-the-uk-s-potential-for-leadership-in-ambi" title="https://www.healthcare.digital/single-post/the-regulatory-vanguard-assessing-the-mhra-ai-airlock-and-the-uk-s-potential-for-leadership-in-ambi" target="_blank" rel="noopener">https://www.healthcare.digital/single-post/the-regulatory-vanguard-assessing-the-mhra-ai-airlock-and-the-uk-s-potential-for-leadership-in-ambi</a>

MHRA AI Airlock and the UK’s Potential for Leadership in Ambient Voice Technology Governance

The Boston Consulting Group (BCG) report, "Innovation for Impact: Unlocking the Potential of the UK’s Healthcare Ecosystem," highlights the UK's strong foundations in healthcare innovation but notes that this potential is not consistently translated into patient impact and economic value.The report identifies a significant untapped economic and societal opportunity, estimating that by 2030, the healthcare sector's contribution to GDP could be approximately £78 billion greater than current projections (a 76% increase), with further substantial benefits for the NHS and society.Key Findings and ChallengesThe report outlines the UK's strengths and the major barriers to innovation adoption and scaling:Strong Foundations: The UK possesses world-class assets, including a prominent life sciences sector, leading academic institutions, rich health data, and the NHS as a unique national platform. Untapped Potential: Despite these strengths, the translation of innovation into widespread patient benefit and economic growth is hampered.Slow Adoption: The UK lags some European peers in the median time for new medicines to reach patients. Economic Lag: The sector's economic contribution is lower than its potential. Barriers to Innovation:Workforce Capacity: There is a lack of capacity and capabilities for translational research and innovation within the NHS, often due to poorly defined career pathways, limited protected time for innovation, and a gap in digital/AI fluency. Cultural and Process Hurdles: NHS staff often lack the support to test, adopt, and scale innovation, facing a risk-averse culture and disjointed policy and regulation. Scaling Difficulty: While innovative solutions are frequently tested in the NHS, the biggest challenge is the successful scaling and diffusion of proven innovations from early-stage, site-specific adoption to national uptake, often limited by regional variability and disparate funding. Long-Term Strategy: A lack of consistent, long-term strategy with collective accountability and sustained investment over a 3- to 10-year horizon prevents overcoming long-standing barriers. Main Recommendations The BCG report, often aligned with the goals of the NHS's own Innovation Ecosystem Programme, generally proposes a strategic and collaborative approach across the ecosystem to unlock this potential:Prioritise and Align Innovation:Focus Goals: Align the innovation ecosystem with the government's major health and economic goals, focusing on shifts like hospital to community, analogue to digital, and sickness to prevention (e.g., early detection, diagnosis, and personalised medicine). Strategic Investment: Establish co-ordinated oversight and align innovation funding to fund fewer but larger pools of money to support scaling. Make Innovation Core to NHS Business:Workforce Integration: Embed innovation as a core part of NHS roles by developing clearer career pathways, providing protected time for innovation, and enhancing digital and AI literacy within the workforce. Incentives and Monitoring: Develop incentives and monitor delivery using Key Performance Indicators (KPIs) for the testing and adoption of innovation to drive accountability. Simplify and Strengthen Structures:Streamline Governance: Simplify overcomplicated oversight structures to allow innovation programs to flourish at the local level while maintaining national consistency. Data and IP: Strengthen data access and information governance to enable better collaboration across the NHS, academia, and industry, which is crucial for leveraging the UK's rich health data assets, especially for AI and genomic research. Local Mobilisation: Encourage and support local systems to take the lead in co-ordination and decision-making for innovation adoption, promoting flexibility and rapid scaling from proven centres of excellence.Source: <a href="https://www.bcg.com/publications/2025/united-kingdom-innovation-for-impact-unlocking-the-potential-of-the-healthcare-ecosystem">https://www.bcg.com/publications/2025/united-kingdom-innovation-for-impact-unlocking-the-potential-of-the-healthcare-ecosystem</a>

BCG Report - Innovation for Impact: Unlocking the Potential of the UK’s Healthcare Ecosystem

Menlo Ventures' inaugural 2025: The State of AI in Healthcare Report finds that the healthcare industry has shed its "laggard" status and is now adopting AI 2.2x faster than the broader economy, driven by a need to combat a cost crisis and staff shortages.The report, based on a survey of over 700 healthcare executives, highlights an explosive growth in spending and a critical shift from piloting to production deployment.Key Findings of the 2025 ReportSurging Spending and Adoption: Total AI spending in healthcare is set to reach $1.4 billion in 2025, nearly tripling the total from the previous year. 22% of healthcare organizations have now deployed domain-specific AI solutions, marking a massive 7x increase over 2024. The Pilot Phase Is Over: The vast majority of the $1.4 billion spend is flowing into production deployments, not just proof-of-concept pilots. Providers account for 75% ($1 billion) of this total spending.Top Use Cases: The largest spending categories are those that address acute operational pain points and offer clear ROI:Ambient Clinical Documentation ($600M): This reduces physician burnout by automatically generating clinical notes.Coding and Billing Automation ($450M): This recovers revenue lost to errors and denials. Fastest-Growing Categories:Patient Engagement is growing at +20x year-over-year. Prior Authorization is growing at +10x year-over-year. Acceleration by Providers, Caution by Payers:Health systems and outpatient providers are dramatically shortening their buying cycles (by 18% and 22%, respectively) to capture operational gains quickly. Payers (insurers) are proceeding more cautiously, as they fear AI tools used by providers to optimize billing may lead to a surge in claims volume and increased medical costs. Startups vs. Incumbents: Startups currently capture 85% of the healthcare AI spending. However, customers report a slight preference for buying AI from their incumbent EHR providers (like Epic and Oracle Health) for critical functions, indicating a future battle for market share. Life Sciences Focus: Pharma and biotech companies are prioritizing building or fine-tuning proprietary models(66%) for R&amp;D data analysis (63%) to accelerate the costly drug discovery lifecycle. This report confirms that AI is becoming an essential part of the operational and clinical workflow, no longer an experimental technology.Source: <a href="https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/">https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/</a>

Menlo Ventures' inaugural 2025: The State of AI in Healthcare Report

The single most significant key point from the Silicon Valley Bank (SVB) Future of HealthTech 2025 report is the dramatic shift of venture capital investment towards AI-enabled Provider Operations. &nbsp;&nbsp; Here's a breakdown of the central finding: &nbsp;&nbsp; Provider Operations Overtakes Alternative Care: Investment in Provider Operations (administrative and back-office functions like scheduling, documentation and billing, which is essential to the delivery of healthcare) now accounts for a massive 44% of total HealthTech funding, surpassing the previous investment leader, alternative care.The AI Driver: This surge is driven by the adoption of AI-enabled solutions aimed at solving business problems and improving efficiency. The report states that 52% of 2025 provider-operations deals involve AI.Record-Setting Investment: This sub-sector is on track to have its biggest investment year ever, projected to break its 2021 record. The Future of HealthTech 2025 Report&nbsp; &nbsp;&nbsp; The Future of HealthTech 2025 Report by Silicon Valley Bank (SVB) highlights a significant shift in venture capital (VC) investment, with a strong focus on AI-enabled provider operations. Key takeaways from the report include: &nbsp; Provider Operations Dominates Funding: Investment is shifting dramatically, with provider operations (activities like scheduling, documentation and billing) capturing 44% of HealthTech funding. This sub-sector is on track for its biggest investment year ever, projected to surpass its 2021 record.The AI Boom: AI-driven solutions are the main catalyst for this shift, transforming administrative and clinical workflows. 52% of 2025 provider-operations deals involve AI, and seed-stage AI valuations have seen a boost of around 42% since 2021.Decline in Alternative Care: Conversely, the share of investment going to alternative care has fallen sharply, from 42% in 2021 to just 9% today.M&amp;A is the Primary Exit Strategy: As initial public offerings (IPOs) remain challenging, consolidation through mergers and acquisitions (M&amp;A) has become the dominant exit strategy, particularly within provider operations.Concentration Risk: The report notes a concentration of capital, with mega-deals (those relying on valuation premiums, often from generalist investors) making up 38% of total Healthtech investment. A significant portion of the total invested in 2025 went to a single company.The report suggests that the HealthTech sector is becoming more focused on solving business and operational inefficiencies using AI, rather than exclusively focusing on clinical care problems. Source: <a data-mce-href="https://www.svb.com/globalassets/trendsandinsights/reports/healthcare/2025/future-of-healthtech-2025-v2.pdf" href="https://www.svb.com/globalassets/trendsandinsights/reports/healthcare/2025/future-of-healthtech-2025-v2.pdf" title="https://www.svb.com/globalassets/trendsandinsights/reports/healthcare/2025/future-of-healthtech-2025-v2.pdf" target="_blank" rel="noopener">https://www.svb.com/globalassets/trendsandinsights/reports/healthcare/2025/future-of-healthtech-2025-v2.pdf</a>

Nelson Advisors

Blog

Biopsychosociotechnical (BPST) Models: One to Watch in He...

Strategic Analysis of the NHS and Microsoft 365 Copilot T...

MHRA AI Airlock and the UK’s Potential for Leadership in ...

BCG Report - Innovation for Impact: Unlocking the Potenti...

Menlo Ventures' inaugural 2025: The State of AI in Health...

Key Points from The Future of HealthTech 2025 report by S...